Latest Period
Q1 2026
Security Snapshot
Eikon Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EIKN) Institutional Ownership
CUSIP: 282564103
13F Institutional Holders and Ownership History for Q1 2026
Institutions Reporting
52
Shares (Excl. Options)
23,743,113
Price
$10.58
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- EIKN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 23,743,113
- Total 13F value
- $251,203,493
- Portfolio coverage rank
- 0%
- Share change
- +22,614,368
- Value change
- +$239,261,371
- Number of holders
- 52
- Shares outstanding
- 54,464,520
- SEC-reported price per share
- $8.77
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EIKN - Eikon Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 282564103.
- 52 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q1 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 52 institutions filings for Q1 2026.
Security key
282564103
Latest holder period
Q1 2026
13F holders
52
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
EIKN full holder history
Eikon Therapeutics, Inc. SEC filings
Eikon Therapeutics, Inc. company facts
Eikon Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 282564103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
EIKN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Foresite Capital Fund IV, L.P. | 7.7% | 4,148,519 | James B. Tananbaum | 04 Feb 2026 | ||||
| FMR LLC | 7.1% | $37,869,512 | 3,836,830 | FMR LLC | 31 Mar 2026 | |||
| BlackRock Portfolio Management LLC | 5.5% | $29,456,850 | 3,002,737 | BlackRock Portfolio Management LLC | 31 Mar 2026 | |||
| PERLMUTTER ROGER M | 5.2% | $28,555,598 | 2,893,171 | PERLMUTTER ROGER M | 04 Feb 2026 | |||
| Abu Dhabi Investment Authority | 5.2% | 2,816,714 | Abu Dhabi Investment Authority | 04 Feb 2026 | ||||
| Innovation Endeavors III LP | 5% | $26,878,241 | 2,723,226 | Innovation Endeavors III LP | 31 Mar 2026 |
As of 31 Mar 2026, 52 institutional investors reported holding 23,743,113 shares of Eikon Therapeutics, Inc. - Common Stock, $0.0001 par value per share (EIKN). This represents 44% of the company’s total 54,464,520 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
41%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 7% | 3,836,830 | 0% | $40,593,661 | |
| BlackRock, Inc. | 6.1% | 3,319,379 | 0% | $35,119,030 | |
| Foresite Capital Management IV, LLC | 3.6% | 1,943,682 | 8.7% | $20,564,156 | |
| Merck & Co., Inc. | 3.1% | 1,666,666 | 5% | $17,633,326 | |
| Foresite Capital Management V, LLC | 2.4% | 1,318,983 | 5.1% | $13,954,840 | |
| T. Rowe Price Investment Management, Inc. | 2.2% | 1,222,487 | 0.01% | $12,934,000 | |
| Capital World Investors | 2.1% | 1,143,637 | 0% | $12,099,679 | |
| ALLIANCEBERNSTEIN L.P. | 1.9% | 1,022,188 | 0% | $10,814,749 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 975,834 | 0% | $10,325,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 969,431 | 0% | 0% | $10,256,580 |
| EcoR1 Capital, LLC | 1.3% | 732,606 | 0.33% | $7,750,971 | |
| BAKER BROS. ADVISORS LP | 1% | 555,555 | 0.03% | $5,877,772 | |
| SOROS CAPITAL MANAGEMENT LLC | 0.89% | 484,672 | 2.2% | $5,127,829 | |
| StepStone Group LP | 0.73% | 395,340 | 2% | $4,182,697 | |
| CANADA PENSION PLAN INVESTMENT BOARD | 0.7% | 379,024 | 0% | $4,010,074 | |
| FRANKLIN RESOURCES INC | 0.64% | 350,000 | 0% | $3,703,000 | |
| CITADEL ADVISORS LLC | 0.57% | 310,000 | 0% | $3,279,800 | |
| General Catalyst Group Management, LLC | 0.56% | 305,233 | 1.8% | $3,229,365 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.5% | 273,931 | 0% | $2,899,956 | |
| JANE STREET GROUP, LLC | 0.49% | 265,000 | 0% | $2,803,700 | |
| Ensign Peak Advisors, Inc | 0.37% | 200,000 | 0% | $2,116,000 | |
| WELLINGTON MANAGEMENT GROUP LLP | 0.34% | 185,000 | 0% | $1,957,300 | |
| MILLENNIUM MANAGEMENT LLC | 0.32% | 175,627 | 0% | $1,858,134 | |
| Blackstone Inc. | 0.31% | 168,338 | 0.01% | $1,781,016 | |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.26% | 140,344 | 0% | $1,484,840 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q1 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 23,743,113 | $251,203,493 | +$239,261,371 | $10.58 | 52 |